{
  "esomeprazole": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline for CYP2C19 and Proton Pump Inhibitor Dosing states that inconsistent findings regarding the effect of CYP2C19 genotype on the pharmacokinetics and therapeutic response to esomeprazole and rabeprazole preclude making recommendations for these proton pump inhibitors.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for esomeprazole, rabeprazole and CYP2C19",
    "url": ""
  },
  "azathioprine": {
    "gene": "See CPIC",
    "advice": "Testing for TPMT genotype and phenotype is recommended for patients who are receiving azathioprine as an immunosuppressant. A dose reduction should be considered for patients with intermediate TPMT activity, while a greater dose reduction or selection of an alternate drug should be considered for patients with low TPMT activity.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of RNPGx Guideline for azathioprine and TPMT",
    "url": ""
  },
  "clozapine": {
    "gene": "See CPIC",
    "advice": "There is no gene-drug interaction between CYP1A2 and clozapine.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for clozapine and CYP1A2",
    "url": ""
  },
  "aripiprazole": {
    "gene": "See CPIC",
    "advice": "The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends reducing maximum dose of aripiprazole for patients carrying poor metabolizer alleles of CYP2D6.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for aripiprazole and CYP2D6",
    "url": ""
  },
  "acenocoumarol": {
    "gene": "See CPIC",
    "advice": "Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of RNPGx Guideline for acenocoumarol, fluindione, warfarin and CYP2C9, VKORC1",
    "url": ""
  },
  "fluorouracil": {
    "gene": "See CPIC",
    "advice": "An Italian working group comprising the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF) has published recommendations for the use of DPYD genotype when prescribing fluoropyrimidines (5-fluorouracil, capecitabine and tegafur).\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of AIOM Guideline for capecitabine, fluorouracil, tegafur and DPYD",
    "url": ""
  },
  "phenprocoumon": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for phenprocoumon dosing based on CYP2C9 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for phenprocoumon and CYP2C9",
    "url": ""
  },
  "moclobemide": {
    "gene": "See CPIC",
    "advice": "No action is needed for this gene-drug interaction.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for moclobemide and CYP2C19",
    "url": ""
  },
  "duloxetine": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone, vortioxetine and SLC6A4",
    "url": ""
  },
  "risperidone": {
    "gene": "See CPIC",
    "advice": "The Dutch Pharmacogenetics Working Group Guideline for risperidone recommends decreasing the dose for CYP2D6 poor metabolizers and using an alternative drug or titrate the dose according to the maximum dose for the active metabolite for CYP2D6 ultrarapid metabolizers.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for risperidone and CYP2D6",
    "url": ""
  },
  "tegafur": {
    "gene": "See CPIC",
    "advice": "An Italian working group comprising the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF) has published recommendations for the use of DPYD genotype when prescribing fluoropyrimidines (5-fluorouracil, capecitabine and tegafur).\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of AIOM Guideline for capecitabine, fluorouracil, tegafur and DPYD",
    "url": ""
  },
  "mercaptopurine": {
    "gene": "See CPIC",
    "advice": "The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends testing for TPMT.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of RNPGx Guideline for mercaptopurine and TPMT",
    "url": ""
  },
  "olanzapine": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for olanzapine dosing based on CYP1A2 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for olanzapine and CYP1A2",
    "url": ""
  },
  "ribavirin": {
    "gene": "See CPIC",
    "advice": "IFNL3 (IL28B) variation (rs12979860) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (rs12979860 CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and IFNL3",
    "url": ""
  },
  "clopidogrel": {
    "gene": "See CPIC",
    "advice": "The American Heart Association has a statement of CYP2C19 and clopidogrel and testing before oral P2Y12 inhibitors are prescribed in patients with acute coronary syndromes or percutaneous coronary intervention.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of AHA Guideline for clopidogrel and CYP2C19",
    "url": ""
  },
  "warfarin": {
    "gene": "See CPIC",
    "advice": "Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of RNPGx Guideline for acenocoumarol, fluindione, warfarin and CYP2C9, VKORC1",
    "url": ""
  },
  "irinotecan": {
    "gene": "See CPIC",
    "advice": "An Italian working group comprising the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF) has published recommendations for the use of UGT1A1*28 (TA7 repeats) genotype when prescribing irinotecan.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of AIOM Guideline for irinotecan and UGT1A1",
    "url": ""
  },
  "glyburide": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "imipramine": {
    "gene": "See CPIC",
    "advice": "Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for imipramine and CYP2C19, CYP2D6",
    "url": ""
  },
  "omeprazole": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (&gt;12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19",
    "url": ""
  },
  "pantoprazole": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (&gt;12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19",
    "url": ""
  },
  "tramadol": {
    "gene": "See CPIC",
    "advice": "Alternate non-codeine analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific dose of tramadol is warranted for CYP2D6 normal and intermediate metabolizers.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for tramadol and CYP2D6",
    "url": ""
  },
  "thioguanine": {
    "gene": "See CPIC",
    "advice": "Select an alternative drug or reduce the initial dose of thioguanine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for thioguanine and NUDT15",
    "url": ""
  },
  "nortriptyline": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for nortriptyline and CYP2D6",
    "url": ""
  },
  "propafenone": {
    "gene": "See CPIC",
    "advice": "Reduce the dose of propafenone by 70% for CYP2D6 poor metabolizers, and monitor propafenone plasma concentrations or use an alternative drug for CYP2D6 intermediate and ultrarapid metabolizers.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for propafenone and CYP2D6",
    "url": ""
  },
  "capecitabine": {
    "gene": "See CPIC",
    "advice": "An Italian working group comprising the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF) has published recommendations for the use of DPYD genotype when prescribing fluoropyrimidines (5-fluorouracil, capecitabine and tegafur).\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of AIOM Guideline for capecitabine, fluorouracil, tegafur and DPYD",
    "url": ""
  },
  "clomipramine": {
    "gene": "See CPIC",
    "advice": "The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to avoid clomipramine in CYP2C19 ultrarapid metabolizer (UM) for Indication OBSESSIVE COMPULSIVE DISORDER or ANXIETY DISORDERS.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for clomipramine and CYP2C19",
    "url": ""
  },
  "tamoxifen": {
    "gene": "See CPIC",
    "advice": "The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) states that there is no recommendation\nfor genotyping CYP2D6 in all patients starting a tamoxifen regimen.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of RNPGx Guideline for tamoxifen and CYP2D6",
    "url": ""
  },
  "mirtazapine": {
    "gene": "See CPIC",
    "advice": "There are currently no dosing recommendations for mirtazapine based on CYP2C19 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for mirtazapine and CYP2C19",
    "url": ""
  },
  "venlafaxine": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone, vortioxetine and SLC6A4",
    "url": ""
  },
  "flecainide": {
    "gene": "See CPIC",
    "advice": "Reduce flecainide dose by 50% for CYP2D6 poor metabolizer (PM) and record an ECG and monitor the plasma concentration. Reduce flecainide dose to 75% of the standard dose for CYP2D6 intermediate metabolizer (IM) patients with indications other than diagnosis of Brugada syndrome and record an ECG and monitor the plasma concentration.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for flecainide and CYP2D6",
    "url": ""
  },
  "codeine": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, morphine, naltrexone, remifentanil, sufentanil, tramadol and COMT, OPRM1",
    "url": ""
  },
  "gliclazide": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mesalazine, moxifloxacin, nicorandil, nitrofurazone, probenecid, quinacrine, sodium nitrate, sulfacetamide, tolazamide, trametinib and G6PD",
    "url": ""
  },
  "oxycodone": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of methadone or oxycodone based on CYP2D6, OPRM1 or COMT genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for methadone, oxycodone and COMT, CYP2D6, OPRM1",
    "url": ""
  },
  "carvedilol": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of carvedilol, labetalol, nadolol, pindolol, propranolol or sotalol based on ADRB2 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for carvedilol, labetalol, nadolol, pindolol, propranolol, sotalol and ADRB2",
    "url": ""
  },
  "escitalopram": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone, vortioxetine and SLC6A4",
    "url": ""
  },
  "paroxetine": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone, vortioxetine and SLC6A4",
    "url": ""
  },
  "citalopram": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone, vortioxetine and SLC6A4",
    "url": ""
  },
  "glimepiride": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mesalazine, moxifloxacin, nicorandil, nitrofurazone, probenecid, quinacrine, sodium nitrate, sulfacetamide, tolazamide, trametinib and G6PD",
    "url": ""
  },
  "sertraline": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone, vortioxetine and SLC6A4",
    "url": ""
  },
  "flupenthixol": {
    "gene": "See CPIC",
    "advice": "There are currently no dosing recommendations for flupenthixol based on CYP2D6 genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for flupenthixol and CYP2D6",
    "url": ""
  },
  "amitriptyline": {
    "gene": "See CPIC",
    "advice": "There are currently no dosing recommendations for amitriptyline based on CYP2C19 genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for amitriptyline and CYP2C19",
    "url": ""
  },
  "tacrolimus": {
    "gene": "See CPIC",
    "advice": "Testing for the CYP3A5*3 and CYP3A4*22 alleles is recommended in patients receiving a kidney, heart or lung transplant. CYP3A extensive or intermediate meatbolizers (EMs or IMs) should be given an initial dose of tacrolimus 1.5-2 times higher than that recommended for CYP3A poor metabolizers (PMs), up to a maximum dose of 0.30 mg/kg/day.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of RNPGx Guideline for tacrolimus and CYP3A4, CYP3A5",
    "url": ""
  },
  "phenytoin": {
    "gene": "See CPIC",
    "advice": "Phenytoin should be avoided if possible in patients with the HLA-B*15:02 allele.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for phenytoin and HLA-B",
    "url": ""
  },
  "rabeprazole": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline for CYP2C19 and Proton Pump Inhibitor Dosing states that inconsistent findings regarding the effect of CYP2C19 genotype on the pharmacokinetics and therapeutic response to esomeprazole and rabeprazole preclude making recommendations for these proton pump inhibitors.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for esomeprazole, rabeprazole and CYP2C19",
    "url": ""
  },
  "tolbutamide": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "lansoprazole": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (&gt;12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19",
    "url": ""
  },
  "haloperidol": {
    "gene": "See CPIC",
    "advice": "The recommendation for CYP2D6 poor metabolizers is to use 60% of the normal dose of haloperidol and for CYP2D6 ultrarapid metabolizers to use 1.5 times the normal dose or to choose an alternative to haloperidol.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for haloperidol and CYP2D6",
    "url": ""
  },
  "atomoxetine": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline for atomoxetine provides therapeutic recommendations for CYP2D6 ultrarapid, normal, intermediate, and poor metabolizer, which includes guidance for plasma drug concentration testing, as a means to estimate atomoxetine exposure, if no clinical response and in the absence of adverse events after 2 weeks of therapy. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for atomoxetine and CYP2D6",
    "url": ""
  },
  "voriconazole": {
    "gene": "See CPIC",
    "advice": "An alternative antifungal agent should be considered instead of voriconazole in patients who are known to be CYP2C19 ultrarapid metabolizers. CYP2C19 genotyping and use of an alternative antifungal agent is also recommended in patients with subtherapeutic voriconazole serum concentrations despite two dose adjustments.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of AusNZ Guideline for voriconazole and CYP2C19",
    "url": ""
  },
  "abacavir": {
    "gene": "See CPIC",
    "advice": "The Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) has established national guidelines and requires mandatory HLA testing prior to prescribing abacavir and abacavir is contraindicated in patients where the HLA-B*57:01 is present.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of RNPGx Guideline for abacavir and HLA-B",
    "url": ""
  },
  "zuclopenthixol": {
    "gene": "See CPIC",
    "advice": "For CYP2D6 poor and intermediate metabolizers, reduce zuclopenthixol dose. For ultrarapid metabolizers, if the effectiveness is insufficient a dose increase not exceeding 1.5x normal dose is suggested.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for zuclopenthixol and CYP2D6",
    "url": ""
  },
  "allopurinol": {
    "gene": "See CPIC",
    "advice": "The Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) has established national guidelines around testing for HLA-B*58:01 prior to prescription of allopurinol to avoid severe cutaneous adverse reactions (SCARs).\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of RNPGx Guideline for allopurinol and HLA-B",
    "url": ""
  },
  "doxepin": {
    "gene": "See CPIC",
    "advice": "There are currently no dosing recommendations for doxepin based on CYP2C19 genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for doxepin and CYP2C19",
    "url": ""
  },
  "metoprolol": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of orally administered beta-blockers based on ADRB1, ADRA2C, GRK4 and/or GRK5 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, nebivolol, pindolol, propranolol, sotalol and ADRA2C, ADRB1, GRK4, GRK5",
    "url": ""
  },
  "trimipramine": {
    "gene": "See CPIC",
    "advice": "Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for trimipramine and CYP2C19, CYP2D6",
    "url": ""
  },
  "desipramine": {
    "gene": "See CPIC",
    "advice": "Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline/nortriptyline and CYP2C19, CYP2D6 to other tricyclics including desipramine. The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for desipramine and CYP2D6",
    "url": ""
  },
  "simvastatin": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for atorvastatin, lovastatin, fluvastatin, pravastatin, pitavastatin, rosuvastatin and simvastatin dosing based on HMGCR, CYP3A4 or CYP3A5 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin and CYP3A4, CYP3A5, HMGCR",
    "url": ""
  },
  "carbamazepine": {
    "gene": "See CPIC",
    "advice": "The Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) has guidance about carbamazepine and oxcarbazepine toxicity and HLA-B*15:02 and HLA-A*31:01.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of RNPGx Guideline for carbamazepine, oxcarbazepine and HLA-A, HLA-B",
    "url": ""
  },
  "peginterferon alfa-2a": {
    "gene": "See CPIC",
    "advice": "IFNL3 (IL28B) variation (rs12979860) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (rs12979860 CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and IFNL3",
    "url": ""
  },
  "peginterferon alfa-2b": {
    "gene": "See CPIC",
    "advice": "IFNL3 (IL28B) variation (rs12979860) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (rs12979860 CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and IFNL3",
    "url": ""
  },
  "ivacaftor": {
    "gene": "See CPIC",
    "advice": "Ivacaftor is suggested for some cystic fibrosis patients with specific CFTR gating mutations, including the R117H or G551D variants.\nNote that the guideline also suggests that ivacaftor should not be used in patients with at least one R117H mutation who are aged under 6 years or aged 12-17 years and with ppFEV1 greater than 90% predicted.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CFF Guideline for ivacaftor and CFTR",
    "url": ""
  },
  "dapsone": {
    "gene": "See CPIC",
    "advice": "High risk drugs should be avoided in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a G6PD variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.\nThe G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for dapsone, methylene blue, pegloticase, rasburicase, tafenoquine, toluidine blue and G6PD",
    "url": ""
  },
  "methylene blue": {
    "gene": "See CPIC",
    "advice": "High risk drugs should be avoided in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a G6PD variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.\nThe G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for dapsone, methylene blue, pegloticase, rasburicase, tafenoquine, toluidine blue and G6PD",
    "url": ""
  },
  "pegloticase": {
    "gene": "See CPIC",
    "advice": "High risk drugs should be avoided in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a G6PD variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.\nThe G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for dapsone, methylene blue, pegloticase, rasburicase, tafenoquine, toluidine blue and G6PD",
    "url": ""
  },
  "rasburicase": {
    "gene": "See CPIC",
    "advice": "High risk drugs should be avoided in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a G6PD variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.\nThe G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for dapsone, methylene blue, pegloticase, rasburicase, tafenoquine, toluidine blue and G6PD",
    "url": ""
  },
  "tafenoquine": {
    "gene": "See CPIC",
    "advice": "High risk drugs should be avoided in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a G6PD variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.\nThe G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for dapsone, methylene blue, pegloticase, rasburicase, tafenoquine, toluidine blue and G6PD",
    "url": ""
  },
  "toluidine blue": {
    "gene": "See CPIC",
    "advice": "High risk drugs should be avoided in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a G6PD variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.\nThe G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for dapsone, methylene blue, pegloticase, rasburicase, tafenoquine, toluidine blue and G6PD",
    "url": ""
  },
  "fosphenytoin": {
    "gene": "See CPIC",
    "advice": "Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (&quot;HLA-B*15:02-positive&quot;) due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for fosphenytoin, phenytoin and CYP2C9, HLA-B",
    "url": ""
  },
  "fluvoxamine": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone, vortioxetine and SLC6A4",
    "url": ""
  },
  "atazanavir": {
    "gene": "See CPIC",
    "advice": "For patients who are UGT1A1 *28/*28, avoidance of atazanavir is recommended if there is a suitable alternative.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for atazanavir and UGT1A1",
    "url": ""
  },
  "daunorubicin": {
    "gene": "See CPIC",
    "advice": "The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of RARG , SLC28A3 , and UGT1A6 when prescribing anthracyclines for pediatric cancer patients. They recommend that pharmacogenomic testing of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6 *4 (rs17863783) should be performed in all pediatric cancer patients who are treated with daunorubicin or doxorubicin because the association of those genetic variants with anthracycline associated cardiotoxicity (ACT).\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPNDS Guideline for daunorubicin, doxorubicin and RARG, SLC28A3, UGT1A6",
    "url": ""
  },
  "doxorubicin": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "ondansetron": {
    "gene": "See CPIC",
    "advice": "The CPIC dosing guideline for ondansetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for ondansetron and CYP2D6",
    "url": ""
  },
  "tropisetron": {
    "gene": "See CPIC",
    "advice": "The CPIC dosing guideline for tropisetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for tropisetron and CYP2D6",
    "url": ""
  },
  "cisplatin": {
    "gene": "See CPIC",
    "advice": "The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of pharmacogenetic testing for TPMT gene variants when prescribing cisplatin in pediatric cancer patients. They recommend testing for the TPMT alleles *2, *3A, *3B or *3C in all pediatric cancer patients due to the association of these alleles with an increased risk of cisplatin-induced ototoxicity.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPNDS Guideline for cisplatin and TPMT",
    "url": ""
  },
  "oxcarbazepine": {
    "gene": "See CPIC",
    "advice": "The Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) has guidance about carbamazepine and oxcarbazepine toxicity and HLA-B*15:02 and HLA-A*31:01.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of RNPGx Guideline for carbamazepine, oxcarbazepine and HLA-A, HLA-B",
    "url": ""
  },
  "efavirenz": {
    "gene": "See CPIC",
    "advice": "Adjust the initial efavirenz dose for patients with the CYP2B6 PM phenotype along with the consideration of age, weight and BMI and titrate the dose to plasma concentration if needed. For patients with the CYP2B6 IM phenotype, determine the efavirenz plasma concentration if side effects occur and reduce the dose if needed.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for efavirenz and CYP2B6",
    "url": ""
  },
  "quinidine": {
    "gene": "See CPIC",
    "advice": "There are currently no dosing recommendations for quinidine based on CYP2D6 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for quinidine and CYP2D6",
    "url": ""
  },
  "ticagrelor": {
    "gene": "See CPIC",
    "advice": "There are currently no dosing recommendations for ticagrelor based on CYP2C19 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for ticagrelor and CYP2C19",
    "url": ""
  },
  "methylphenidate": {
    "gene": "See CPIC",
    "advice": "There are currently no dosing recommendations for methylphenidate based on COMT genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for methylphenidate and COMT",
    "url": ""
  },
  "gefitinib": {
    "gene": "See CPIC",
    "advice": "There are currently no dosing recommendations for gefitinib based on CYP2D6 genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for gefitinib and CYP2D6",
    "url": ""
  },
  "flucloxacillin": {
    "gene": "See CPIC",
    "advice": "Monitor for liver function and select an alternative drug instead of flucloxacillin if liver enzymes or bilirubin is elevated, for patients that are HLA-B*57:01.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for flucloxacillin and HLA-B",
    "url": ""
  },
  "disopyramide": {
    "gene": "See CPIC",
    "advice": "There are currently no dosing recommendations for disopyramide based on CYP2D6 genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for disopyramide and CYP2D6",
    "url": ""
  },
  "amiodarone": {
    "gene": "See CPIC",
    "advice": "There are currently no dosing recommendations for amiodarone based on CYP2D6 genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for amiodarone and CYP2D6",
    "url": ""
  },
  "bisoprolol": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of orally administered beta-blockers based on ADRB1, ADRA2C, GRK4 and/or GRK5 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, nebivolol, pindolol, propranolol, sotalol and ADRA2C, ADRB1, GRK4, GRK5",
    "url": ""
  },
  "clonidine": {
    "gene": "See CPIC",
    "advice": "There are currently no dosing recommendations for clonidine based on CYP2D6 genotype and DPWG suggest clonidine as possible alternative for atomoxetine in variant CYP2D6 metabolisers.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for clonidine and CYP2D6",
    "url": ""
  },
  "pimozide": {
    "gene": "See CPIC",
    "advice": "Patients who are CYP2D6 intermediate metabolizers should be given no more than 80% of the standard maximum dose of pimozide while patients who are CYP2D6 poor metabolizers should be given no more than 50% of the standard maximum dose.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for pimozide and CYP2D6",
    "url": ""
  },
  "prasugrel": {
    "gene": "See CPIC",
    "advice": "There are currently no dosing recommendations for prasugrel based on CYP2C19 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for prasugrel and CYP2C19",
    "url": ""
  },
  "atenolol": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of orally administered beta-blockers based on ADRB1, ADRA2C, GRK4 and/or GRK5 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, nebivolol, pindolol, propranolol, sotalol and ADRA2C, ADRB1, GRK4, GRK5",
    "url": ""
  },
  "eliglustat": {
    "gene": "See CPIC",
    "advice": "The Dutch Pharmacogenetics Working Group Guideline for eliglustat recommends to use an alternative in CYP2D6 ultrarapid metabolizer. For CYP2D6 poor metabolizer in combination with CYP3A inhibitors and strong inducers, the guideline recommends to choose an alternative if possible. For intermediate metabolizers recommendations are provided for renal and hepatic impairment.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for eliglustat and CYP2D6",
    "url": ""
  },
  "atorvastatin": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for atorvastatin, lovastatin, fluvastatin, pravastatin, pitavastatin, rosuvastatin and simvastatin dosing based on HMGCR, CYP3A4 or CYP3A5 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin and CYP3A4, CYP3A5, HMGCR",
    "url": ""
  },
  "fluvastatin": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for atorvastatin, lovastatin, fluvastatin, pravastatin, pitavastatin, rosuvastatin and simvastatin dosing based on HMGCR, CYP3A4 or CYP3A5 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin and CYP3A4, CYP3A5, HMGCR",
    "url": ""
  },
  "fluoxetine": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone, vortioxetine and SLC6A4",
    "url": ""
  },
  "quetiapine": {
    "gene": "See CPIC",
    "advice": "Patients who are CYP3A4 poor metabolizers and being treated for depression should be given an alternative drug. Patients being treated for other indications and who are CYP3A4 poor metabolizers should be given a reduced dose of quetiapine. No action is needed for patients who are CYP3A4 intermediate metabolizers.\nClinPGx uses CYP3A4 allele nomenclature as defined by PharmVar, while the current version of this guideline issued by the DPWG uses retired allele names. Further details are given on the DPWG curation page.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for quetiapine and CYP3A4",
    "url": ""
  },
  "sotalol": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of carvedilol, labetalol, nadolol, pindolol, propranolol or sotalol based on ADRB2 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for carvedilol, labetalol, nadolol, pindolol, propranolol, sotalol and ADRB2",
    "url": ""
  },
  "brexpiprazole": {
    "gene": "See CPIC",
    "advice": "The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to use half of the normal dose of brexpiprazole for poor metabolizers of CYP2D6.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for brexpiprazole and CYP2D6",
    "url": ""
  },
  "celecoxib": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of\nthe lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for celecoxib, flurbiprofen, ibuprofen, lornoxicam and CYP2C9",
    "url": ""
  },
  "flurbiprofen": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of\nthe lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for celecoxib, flurbiprofen, ibuprofen, lornoxicam and CYP2C9",
    "url": ""
  },
  "ibuprofen": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for NSAIDs dosing based on CYP2C8 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for diclofenac, ibuprofen and CYP2C8",
    "url": ""
  },
  "lornoxicam": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of\nthe lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for celecoxib, flurbiprofen, ibuprofen, lornoxicam and CYP2C9",
    "url": ""
  },
  "meloxicam": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline for meloxicam recommends alternative therapy for CYP2C9 poor metabolizers due to markedly prolonged half-life, and initiating therapy with 50% of the lowest recommended starting dose or choose an alternative therapy for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for meloxicam and CYP2C9",
    "url": ""
  },
  "piroxicam": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline for piroxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for piroxicam and CYP2C9",
    "url": ""
  },
  "tenoxicam": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline for tenoxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for tenoxicam and CYP2C9",
    "url": ""
  },
  "HMG-CoA reductase inhibitors": {
    "gene": "See CPIC",
    "advice": "Testing for rs4149056 before starting statin treatment, or early after treatment onset (potentially useful test) is recommended in patients with one or more risk factors described (as a function of statin type and dose, co-medications, and the pathophysiological or genetic setting). If the genotype is not known early, the RNPGx considers that a polymorphism test is potentially useful in the event of muscle toxicity in patients treated with statins, in order to rule out or confirm a genetic cause.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of RNPGx Guideline for hmg coa reductase inhibitors, simvastatin and SLCO1B1",
    "url": ""
  },
  "fluindione": {
    "gene": "See CPIC",
    "advice": "Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of RNPGx Guideline for acenocoumarol, fluindione, warfarin and CYP2C9, VKORC1",
    "url": ""
  },
  "antidepressants": {
    "gene": "See CPIC",
    "advice": "The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends CYP2D6 and CYP2C19 genotyping before initiating an antidepressant treatment, especially in patients with a high risk of toxicity.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of RNPGx Guideline for antidepressants and CYP2C19, CYP2D6",
    "url": ""
  },
  "methotrexate": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for methotrexate dosing based on MTHFR rs1801133 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for methotrexate and MTHFR",
    "url": ""
  },
  "siponimod": {
    "gene": "See CPIC",
    "advice": "The Dutch Pharmacogenetics Working Group Guideline for siponimod recommends decreasing the dose for CYP2C9 *1/*3, *2/*3 genotypes or CYP2C9 intermediate metabolizer (not including *2 and *3) and to avoid siponimod for the CYP2C9 *3/*3 genotype or CYP2C9 poor metabolizer (two alleles with no/decreased enzyme activity, of which at least one other than *2 or *3).\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for siponimod and CYP2C9",
    "url": ""
  },
  "dexlansoprazole": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline recommendations for dexlansoprazole are based on the similarity in its metabolism and lansoprazole and extrapolated from the first-generation PPIs. The guideline recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizers for chronic therapy (&gt;12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for dexlansoprazole and CYP2C19",
    "url": ""
  },
  "diclofenac": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen based on CYP2C9 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aceclofenac, aspirin, diclofenac, dipyrone, indomethacin, lumiracoxib, nabumetone, naproxen and CYP2C9",
    "url": ""
  },
  "aceclofenac": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen based on CYP2C9 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aceclofenac, aspirin, diclofenac, dipyrone, indomethacin, lumiracoxib, nabumetone, naproxen and CYP2C9",
    "url": ""
  },
  "aspirin": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid aspirin at doses of ≤1g/day in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), aspirin ≤1g/day should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. CPIC gives a 'no recommendation' for the use of G6PD genotype for prescribing aspirin at doses &gt;1g/day. In summary, CPIC either does not provide, or recommend changing, prescribing actions based on G6PD genotype for aspirin at any dose.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aspirin and G6PD",
    "url": ""
  },
  "dipyrone": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen based on CYP2C9 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aceclofenac, aspirin, diclofenac, dipyrone, indomethacin, lumiracoxib, nabumetone, naproxen and CYP2C9",
    "url": ""
  },
  "indomethacin": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen based on CYP2C9 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aceclofenac, aspirin, diclofenac, dipyrone, indomethacin, lumiracoxib, nabumetone, naproxen and CYP2C9",
    "url": ""
  },
  "lumiracoxib": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen based on CYP2C9 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aceclofenac, aspirin, diclofenac, dipyrone, indomethacin, lumiracoxib, nabumetone, naproxen and CYP2C9",
    "url": ""
  },
  "nabumetone": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen based on CYP2C9 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aceclofenac, aspirin, diclofenac, dipyrone, indomethacin, lumiracoxib, nabumetone, naproxen and CYP2C9",
    "url": ""
  },
  "naproxen": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen based on CYP2C9 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aceclofenac, aspirin, diclofenac, dipyrone, indomethacin, lumiracoxib, nabumetone, naproxen and CYP2C9",
    "url": ""
  },
  "flucytosine": {
    "gene": "See CPIC",
    "advice": "The Dutch Pharmacogenetics Working Group Guideline for flucytosine states that patients with a DPYD activity score of 0 should avoid flucytosine. Patients with a DPYD activity score of 1 or 1.5 should be alert to the occurrence of severe side effects and flucytosine should be stopped if severe side effects occur.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for flucytosine and DPYD",
    "url": ""
  },
  "alfentanil": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, morphine, naltrexone, remifentanil, sufentanil, tramadol and COMT, OPRM1",
    "url": ""
  },
  "buprenorphine": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, morphine, naltrexone, remifentanil, sufentanil, tramadol and COMT, OPRM1",
    "url": ""
  },
  "fentanyl": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, morphine, naltrexone, remifentanil, sufentanil, tramadol and COMT, OPRM1",
    "url": ""
  },
  "hydrocodone": {
    "gene": "See CPIC",
    "advice": "CYP2D6 intermediate and poor metabolizers should initiate hydrocodone therapy using the label recommended age- or weight-specific dosing. However, if there is no response to hydrocodone in these patients, an alternative analgesic should be considered.\nThere is insufficient evidence to provide a dosing recommendation for hydrocodone in CYP2D6 ultrarapid metabolizers.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for hydrocodone and CYP2D6",
    "url": ""
  },
  "hydromorphone": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, morphine, naltrexone, remifentanil, sufentanil, tramadol and COMT, OPRM1",
    "url": ""
  },
  "levomethadone": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, morphine, naltrexone, remifentanil, sufentanil, tramadol and COMT, OPRM1",
    "url": ""
  },
  "morphine": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, morphine, naltrexone, remifentanil, sufentanil, tramadol and COMT, OPRM1",
    "url": ""
  },
  "naltrexone": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, morphine, naltrexone, remifentanil, sufentanil, tramadol and COMT, OPRM1",
    "url": ""
  },
  "remifentanil": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, morphine, naltrexone, remifentanil, sufentanil, tramadol and COMT, OPRM1",
    "url": ""
  },
  "sufentanil": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, morphine, naltrexone, remifentanil, sufentanil, tramadol and COMT, OPRM1",
    "url": ""
  },
  "methadone": {
    "gene": "See CPIC",
    "advice": "CPIC does not currently provide CYP2B6 genotype-based prescribing recommendations for methadone.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for methadone and CYP2B6",
    "url": ""
  },
  "amikacin": {
    "gene": "See CPIC",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for amikacin, dibekacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, plazomicin, ribostamycin, streptomycin, tobramycin and MT-RNR1",
    "url": ""
  },
  "dibekacin": {
    "gene": "See CPIC",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for amikacin, dibekacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, plazomicin, ribostamycin, streptomycin, tobramycin and MT-RNR1",
    "url": ""
  },
  "gentamicin": {
    "gene": "See CPIC",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for amikacin, dibekacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, plazomicin, ribostamycin, streptomycin, tobramycin and MT-RNR1",
    "url": ""
  },
  "kanamycin": {
    "gene": "See CPIC",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for amikacin, dibekacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, plazomicin, ribostamycin, streptomycin, tobramycin and MT-RNR1",
    "url": ""
  },
  "neomycin": {
    "gene": "See CPIC",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for amikacin, dibekacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, plazomicin, ribostamycin, streptomycin, tobramycin and MT-RNR1",
    "url": ""
  },
  "netilmicin": {
    "gene": "See CPIC",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for amikacin, dibekacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, plazomicin, ribostamycin, streptomycin, tobramycin and MT-RNR1",
    "url": ""
  },
  "paromomycin": {
    "gene": "See CPIC",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for amikacin, dibekacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, plazomicin, ribostamycin, streptomycin, tobramycin and MT-RNR1",
    "url": ""
  },
  "plazomicin": {
    "gene": "See CPIC",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for amikacin, dibekacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, plazomicin, ribostamycin, streptomycin, tobramycin and MT-RNR1",
    "url": ""
  },
  "ribostamycin": {
    "gene": "See CPIC",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for amikacin, dibekacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, plazomicin, ribostamycin, streptomycin, tobramycin and MT-RNR1",
    "url": ""
  },
  "streptomycin": {
    "gene": "See CPIC",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for amikacin, dibekacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, plazomicin, ribostamycin, streptomycin, tobramycin and MT-RNR1",
    "url": ""
  },
  "tobramycin": {
    "gene": "See CPIC",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for amikacin, dibekacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, plazomicin, ribostamycin, streptomycin, tobramycin and MT-RNR1",
    "url": ""
  },
  "lovastatin": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for atorvastatin, lovastatin, fluvastatin, pravastatin, pitavastatin, rosuvastatin and simvastatin dosing based on HMGCR, CYP3A4 or CYP3A5 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin and CYP3A4, CYP3A5, HMGCR",
    "url": ""
  },
  "pitavastatin": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for atorvastatin, lovastatin, fluvastatin, pravastatin, pitavastatin, rosuvastatin and simvastatin dosing based on HMGCR, CYP3A4 or CYP3A5 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin and CYP3A4, CYP3A5, HMGCR",
    "url": ""
  },
  "pravastatin": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for pravastatin dosing based on SLCO1B1 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for pravastatin and SLCO1B1",
    "url": ""
  },
  "rosuvastatin": {
    "gene": "See CPIC",
    "advice": "Keep the rosuvastatin dose as low as possible (e.g. by adding ezetimibe) for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, advise the patients to contact their doctor in the event of muscle symptoms.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for rosuvastatin and SLCO1B1",
    "url": ""
  },
  "folic acid": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for folic acid dosing based on MTHFR rs1801133 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for folic acid and MTHFR",
    "url": ""
  },
  "paclitaxel": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for paclitaxel dosing based on CYP3A4 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for paclitaxel and CYP3A4",
    "url": ""
  },
  "lamotrigine": {
    "gene": "See CPIC",
    "advice": "Avoid lamotrigine in patients with HLA-B*15:02 if an alternative is available. If avoidance is not possible, advise to report any rash immediately.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for lamotrigine and HLA-B",
    "url": ""
  },
  "chlorpropamide": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mesalazine, moxifloxacin, nicorandil, nitrofurazone, probenecid, quinacrine, sodium nitrate, sulfacetamide, tolazamide, trametinib and G6PD",
    "url": ""
  },
  "dabrafenib": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mesalazine, moxifloxacin, nicorandil, nitrofurazone, probenecid, quinacrine, sodium nitrate, sulfacetamide, tolazamide, trametinib and G6PD",
    "url": ""
  },
  "glipizide": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mesalazine, moxifloxacin, nicorandil, nitrofurazone, probenecid, quinacrine, sodium nitrate, sulfacetamide, tolazamide, trametinib and G6PD",
    "url": ""
  },
  "mesalazine": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mesalazine, moxifloxacin, nicorandil, nitrofurazone, probenecid, quinacrine, sodium nitrate, sulfacetamide, tolazamide, trametinib and G6PD",
    "url": ""
  },
  "moxifloxacin": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mesalazine, moxifloxacin, nicorandil, nitrofurazone, probenecid, quinacrine, sodium nitrate, sulfacetamide, tolazamide, trametinib and G6PD",
    "url": ""
  },
  "nicorandil": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mesalazine, moxifloxacin, nicorandil, nitrofurazone, probenecid, quinacrine, sodium nitrate, sulfacetamide, tolazamide, trametinib and G6PD",
    "url": ""
  },
  "nitrofurazone": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mesalazine, moxifloxacin, nicorandil, nitrofurazone, probenecid, quinacrine, sodium nitrate, sulfacetamide, tolazamide, trametinib and G6PD",
    "url": ""
  },
  "probenecid": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mesalazine, moxifloxacin, nicorandil, nitrofurazone, probenecid, quinacrine, sodium nitrate, sulfacetamide, tolazamide, trametinib and G6PD",
    "url": ""
  },
  "quinacrine": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mesalazine, moxifloxacin, nicorandil, nitrofurazone, probenecid, quinacrine, sodium nitrate, sulfacetamide, tolazamide, trametinib and G6PD",
    "url": ""
  },
  "sodium nitrate": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mesalazine, moxifloxacin, nicorandil, nitrofurazone, probenecid, quinacrine, sodium nitrate, sulfacetamide, tolazamide, trametinib and G6PD",
    "url": ""
  },
  "sulfacetamide": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mesalazine, moxifloxacin, nicorandil, nitrofurazone, probenecid, quinacrine, sodium nitrate, sulfacetamide, tolazamide, trametinib and G6PD",
    "url": ""
  },
  "tolazamide": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mesalazine, moxifloxacin, nicorandil, nitrofurazone, probenecid, quinacrine, sodium nitrate, sulfacetamide, tolazamide, trametinib and G6PD",
    "url": ""
  },
  "trametinib": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mesalazine, moxifloxacin, nicorandil, nitrofurazone, probenecid, quinacrine, sodium nitrate, sulfacetamide, tolazamide, trametinib and G6PD",
    "url": ""
  },
  "primaquine": {
    "gene": "See CPIC",
    "advice": "Primaquine should be avoided in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA) in most cases, with some exceptions for G6PD deficient patients without CNSHA. In patients with a G6PD variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.\nThe G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for primaquine and G6PD",
    "url": ""
  },
  "nitrofurantoin": {
    "gene": "See CPIC",
    "advice": "Nitrofurantoin should be use with caution in G6PD deficient patients without chronic non-spherocytic hemolytic anemia (CNSHA) and completely avoided by G6PD deficient patients with CNSHA. In patients with a G6PD variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.\nThe G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for nitrofurantoin and G6PD",
    "url": ""
  },
  "aminosalicylic acid": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "chloramphenicol": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "chloroquine": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "ciprofloxacin": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "dimercaprol": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "furazolidone": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "hydroxychloroquine": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "mafenide": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "nalidixic acid": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "norfloxacin": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "ofloxacin": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "phenazopyridine": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "quinine": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "sulfadiazine": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "sulfamethazine": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "sulfamethoxazole": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "sulfamethoxazole / trimethoprim": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "sulfanilamide": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "sulfasalazine": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "sulfisoxazole": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "vitamin c": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "Vitamin K and analogues": {
    "gene": "See CPIC",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",
    "url": ""
  },
  "vortioxetine": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone, vortioxetine and SLC6A4",
    "url": ""
  },
  "desvenlafaxine": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone, vortioxetine and SLC6A4",
    "url": ""
  },
  "levomilnacipran": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone, vortioxetine and SLC6A4",
    "url": ""
  },
  "milnacipran": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone, vortioxetine and SLC6A4",
    "url": ""
  },
  "vilazodone": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone, vortioxetine and SLC6A4",
    "url": ""
  },
  "desflurane": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1",
    "url": ""
  },
  "enflurane": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1",
    "url": ""
  },
  "halothane": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1",
    "url": ""
  },
  "isoflurane": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1",
    "url": ""
  },
  "methoxyflurane": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1",
    "url": ""
  },
  "sevoflurane": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1",
    "url": ""
  },
  "succinylcholine": {
    "gene": "See CPIC",
    "advice": "The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1",
    "url": ""
  },
  "acebutolol": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of orally administered beta-blockers based on ADRB1, ADRA2C, GRK4 and/or GRK5 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, nebivolol, pindolol, propranolol, sotalol and ADRA2C, ADRB1, GRK4, GRK5",
    "url": ""
  },
  "betaxolol": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of orally administered beta-blockers based on ADRB1, ADRA2C, GRK4 and/or GRK5 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, nebivolol, pindolol, propranolol, sotalol and ADRA2C, ADRB1, GRK4, GRK5",
    "url": ""
  },
  "nebivolol": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of orally administered beta-blockers based on ADRB1, ADRA2C, GRK4 and/or GRK5 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, nebivolol, pindolol, propranolol, sotalol and ADRA2C, ADRB1, GRK4, GRK5",
    "url": ""
  },
  "propranolol": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of carvedilol, labetalol, nadolol, pindolol, propranolol or sotalol based on ADRB2 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for carvedilol, labetalol, nadolol, pindolol, propranolol, sotalol and ADRB2",
    "url": ""
  },
  "esmolol": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of orally administered beta-blockers based on ADRB1, ADRA2C, GRK4 and/or GRK5 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, nebivolol, pindolol, propranolol, sotalol and ADRA2C, ADRB1, GRK4, GRK5",
    "url": ""
  },
  "labetalol": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of carvedilol, labetalol, nadolol, pindolol, propranolol or sotalol based on ADRB2 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for carvedilol, labetalol, nadolol, pindolol, propranolol, sotalol and ADRB2",
    "url": ""
  },
  "nadolol": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of carvedilol, labetalol, nadolol, pindolol, propranolol or sotalol based on ADRB2 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for carvedilol, labetalol, nadolol, pindolol, propranolol, sotalol and ADRB2",
    "url": ""
  },
  "pindolol": {
    "gene": "See CPIC",
    "advice": "There are currently no recommendations for dosing of carvedilol, labetalol, nadolol, pindolol, propranolol or sotalol based on ADRB2 genotypes.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for carvedilol, labetalol, nadolol, pindolol, propranolol, sotalol and ADRB2",
    "url": ""
  },
  "mavacamten": {
    "gene": "See CPIC",
    "advice": "The Dutch Pharmacogenetics Working Group Guideline for mavacamten recommends a lower dose for CYP2C19 poor metabolizers and to avoid mavacamten in CYP2C19 poor metabolizers with strong CYP3A4 inhibitor as co-medication.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of DPWG Guideline for mavacamten and CYP2C19",
    "url": ""
  },
  "hydralazine": {
    "gene": "See CPIC",
    "advice": "Consider a starting total daily dose of hydralazine of at least 75 mg. for patients who are NAT2 rapid metabolizers and NAT2 intermediate metabolizers and titrate up to 300 mg as tolerated. For patients who are NAT2 poor metabolizers, initiate therapy at a total daily dose of hydralazine of 40 to 75 mg and carefully titrate upwards; use caution with total daily hydralazine doses of 200 mg or more.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of CPIC Guideline for hydralazine and NAT2",
    "url": ""
  },
  "tebentafusp": {
    "gene": "See CPIC",
    "advice": "The Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) requires testing for HLA-A*02:01 to select patients with metastatic uveal melanoma suitable for treatment with tebentafusp.\n",
    "source": "CPIC Guidelines",
    "guidelineName": "Annotation of RNPGx Guideline for tebentafusp and HLA-A",
    "url": ""
  }
}